

Table. Number (%) of Patients Taking Concomitant Antiseizure Medication (ASM) at Baseline, Those Who Remained or Discontinued Cenobamate, and Mean Dose Adjustments by ASM at Time of Post-hoc Analysis

Concomitant Antiseizure Medication	Taking at Baseline, n (%)^a	Remained on Cenobamate, n (%)^b	Discontinued Cenobamate, n (%)^b	Mean Dose Adjustment in Patients Who Remained on Cenobamate, Change in mg	Mean Dose Adjustment in Patients Who Discontinued Cenobamate, Change in mg
Lacosamide	102 (41.0)	79 (77.5)	23 (22.5)	-176.6	-90.3
Levetiracetam	88 (35.3)	64 (72.7)	24 (27.3)	-800.8	-333.3
Lamotrigine	69 (27.7)	52 (75.4)	17 (24.6)	-115.4	-89.7
Clobazam	40 (16.1)	31 (77.5)	9(22.5)	-24.2	-10.0
Zonisamide	37 (14.9)	30 (81.1)	7 (18.9)	-136.7	-42.8
Valproate	24 (9.6)	15 (62.5)	9 (37.5)	-450.0	-55.6
Topiramate	23 (9.2)	15 (65.2)	8 (34.8)	-90.0	-156.2
Carbamazepine	22 (8.8)	14 (63.6)	8 (36.4)	-442.8	-314.3
Oxcarbazepine	19 (7.6)	16 (84.2)	3 (15.8)	-487.5	-112.5
Phenytoin	18 (7.2)	12 (66.7)	6 (33.3)	-255.8	-257.5
Perampanel	17 (6.8)	17 (100.0)	0 (0.0)	-4.3	NA
Eslicarbazepine	17 (6.8)	13 (76.5)	4 (23.5)	-707.7	0.0
Pregabalin	13 (5.2)	10 (76.9)	3 (23.1)	-210.0	-250
Brivaracetam	12 (4.8)	10 (83.3)	2 (16.7)	-90.0	0.0
Clonazepam	8 (3.2)	4 (50.0)	4 (50.0)	+0.12	0.0
Phenobarbital	7 (2.8)	3 (42.9)	4 (57.1)	-40.8	-77.4
Gabapentin	5 (2.0)	4 (80.0)	1 (20.0)	-1400.0	0.0
Felbamate	4 (1.6)	4 (100.0)	0 (0.0)	-700.0	NA
Clorazepate	3 (1.2)	2 (66.7)	1 (33.3)	-3.8	-7.5
Rufinamide	1 (0.4)	1 (100.0)	0 (0.0)	-800.0	NA

^aPercentages calculated from a total of 249 patients.

^bPercentages calculated from total number of patients taking the specific concomitant drug at baseline.